Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical models Clinical data supports co-administration of an MC4R agonist with tirzepatide as a safe, potentially synergistic approach to weight management PL7737 IND-enabling...